Comparative study of Homoeopathy as add on therapy to standard medical management in persons with Haemophilia (PWH)

Homoeopathy as adjuvant therapy to standard medical management in persons with Haemophilia (PWH)- An exploratory comparative study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/09/021435

Enrollment

150

Registered

2019-09-27

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D67- Hereditary factor IX deficiency Health Condition 2: D66- Hereditary factor VIII deficiency

Interventions

Intervention1: Standard conventional (allopathic/modern medicines): Known Pharmacopoeial Preparations. Control Intervention1: Standard conventional (allopathic/modern medicines) and homoeopathic medic

Eligibility

Inclusion criteria

Inclusion criteria: 1.PWH 10- 45 yrs, diagnosed with severe or moderate Haemophilia A/B under standard medical management 2. PWH willing to take adjuvant homoeopathic treatment for Haemophilia 3. Patients willing to sign written informed consent

Exclusion criteria

Exclusion criteria: 1.Presence of inhibitors 2.PWH with a history of life-threatening bleeds 3.PWH having active hepatitis or positive hepatitis virus B/C serology 4.PWH with HIV/ AIDS or positive HIV serology 5.Hb less than 8 gm%

Design outcomes

Primary

Measure	Time frame
-Annualized bleeding rate for all bleeds (ABRall) at the end of 2 years -Annualized bleeding rate for joint bleeds (ABRjoints) at the end of 2 yearsTimepoint: -Annualized bleeding rate for all bleeds (ABRall) at the end of 2 years -Annualized bleeding rate for joint bleeds (ABRjoints) at the end of 2 years	—

Secondary

Measure	Time frame
-Haemophilia joint health score (HJHS) Timepoint: 6,12,18 and 24 month;Functional Independence Score (FISH)Timepoint: 6, 12 ,18 and 24 month;Haemo QoL/SF-36 scoreTimepoint: 12 and 24 month;Number of PWH developing inhibitorsTimepoint: 1st and 2nd year;Requirement for clotting factor concentrates annuallyTimepoint: 1st and 2nd year;Requirement for pain relieving medicines annually Timepoint: 1st and 2nd year;Time taken to control pain in acute bleeding episodesTimepoint: Each episode of acute bleeding;Time taken to resolve joint swelling in acute bleeding episodesTimepoint: Each episode of acute bleeding	—

Measure

Time frame

-Haemophilia joint health score (HJHS) Timepoint: 6,12,18 and 24 month;Functional Independence Score (FISH)Timepoint: 6, 12 ,18 and 24 month;Haemo QoL/SF-36 scoreTimepoint: 12 and 24 month;Number of PWH developing inhibitorsTimepoint: 1st and 2nd year;Requirement for clotting factor concentrates annuallyTimepoint: 1st and 2nd year;Requirement for pain relieving medicines annually Timepoint: 1st and 2nd year;Time taken to control pain in acute bleeding episodesTimepoint: Each episode of acute bleeding;Time taken to resolve joint swelling in acute bleeding episodesTimepoint: Each episode of acute bleeding

—

Countries

India

Contacts

Public ContactProf Dr Tapas Kundu

Central Council for Research in Homoeopathy

anil23101961@gmail.com9911127619

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026